Longs---if you thought .0008 was a good time to bu

Quote:

---

[From Sree, Update.

Thanks for your message. Yes, I believe withdrawing to resubmit the non-gender is better suited to accomplish our marketing goals, especially given the new data from the neck study. The FDA is definitely responding faster to submissions, so we can look forward to that.

The Recovery Rx 510(k) was submitted in February. As noted in the press releases, we are preparing to send our response to the FDA's request for information on the data in the RecoveryRx. As for Allay, we are expecting a timely completion but since it's an independently conducted study we can only rely on word from the PI.

Thank you for the support! /quote]

---